Nasdaq

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive findings from the ...
Nasdaq

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, ...
Business Wire

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that ...
Pharmabiz

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026: London, UK Frid ...
Bay Area Reporter

FDA approves first injectable HIV regimen

The federal Food and Drug Administration has approved Cabenuva, the first complete long-acting injectable HIV regimen that does not require daily pills. It is approved for people with an undetectable ...
Monthly Prescribing Reference

Cabenuva Label Update Makes Oral Lead-In Dosing Optional

Cabenuva injection is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor. The ...
Medscape

FDA Approves HIV Injectable Cabenuva Initiation Without Oral Lead-in

Initiating treatment may become easier for adults living with HIV. The US Food and Drug Administration has approved a label update that allows adults living with HIV to begin treatment with Cabenuva ...
Monthly Prescribing Reference

Cabenuva Approved as First Long-Acting Injectable for HIV Treatment

The approval of Cabenuva was based on data from two phase 3 trials which included 1182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) prior to initiation. The ...
Yahoo

GSK says it is within weeks of resubmitting HIV injection Cabenuva

Add Yahoo as a preferred source to see more of our stories on Google. A GSK logo is seen on a flag at a GSK research centre in Stevenage FRANKFURT (Reuters) - GlaxoSmithKline's HIV business ViiV is ...
Yahoo

GSK logs win as Health Canada approves its monthly HIV injection

Add Yahoo as a preferred source to see more of our stories on Google. A GSK logo is seen at the GSK research centre in Stevenage (Reuters) - GlaxoSmithKline's HIV treatments division has received ...
Business Wire

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ...